The Codex DNA BioXp\u2122 3250 system is an automatic system that features a benchtop platform for synthetic biology to workflow which accelerates the event of critical new vaccines and biologics.<\/p>\n
Codex DNA Incorporation is the creators of the world\u2019s first fully automatic system for high-throughput DNA printing. They introduced their upcoming next-generation platform which is the BioXp\u2122 3250 system which reduces the timelines for identifying vaccine and biologic drug candidates from weeks to days. They perform the steps necessary to synthesize, assemble, and clone synthetic genes into a single overnight run. Using an Integrated complete automated solution into workflow enables scientists with the pliability to urge large pieces of DNA \u2013 up to 7,000 base pairs long and at unprecedented rates with high accuracy. This system presents itself as a platform that accelerates the numerous synthetic biology workflows which include the invention of vaccines and biologics. It also has genome engineering and editing.<\/p>\n
Todd R. Nelson (Ph.D.)- Founder and Chief military officer at Codex DNA commented that \u201cWe are extremely excited to launch the BioXp\u2122 3250 system which is a full-stack synthetic biologic solution that gives end-to-end enablement of DNA libraries, large genomic DNA assemblies, automated cloning, and cell-free DNA amplification. We can now optimize certain steps of drug discovery faster than anyone on the earth .\u201d<\/p>\n
The COVID-19 pandemic has driven the extraordinary demand for this system and has accelerated their research and development of vaccines. By automatically assembling this error-free viral gene and gene fragments overnight reduces the timelines for identifying vaccine candidates from weeks to months and months to days. Nelson showed the importance by stating – \u201cThe BioXp\u2122 3250 system offers a critical solution to common bottlenecks in vaccine development, directly facilitating the power to urge potentially vital vaccines on the market.\u201d<\/p>\n
The BioXp\u2122 3250 system automates the power to gauge a specific segment of a gene with hi-fi , precision, and accuracy; this is often particularly true within the field of drug discovery for biologics such as antibody-based therapeutics. With a capability to create libraries for all critically acclaimed binding regions of an antibody. We need to improve the speed with which biologic drug candidates can move through the pipeline, irrespective of the targeted disease.
\n\u201cGiven the advantage of the present workflow, we expect the immediate widespread adoption of this platform. In many cases, this gene function and pathway elucidation timelines are getting to be decreased by the utmost amount as 50-fold, providing an enormous advantage to users,\u201d said Dan Gibson, PhD, Chief Technology Officer of Codex DNA.<\/p>\n
\u201cOur goal is to bring revolutionary tools to plug with this new evolution in automated gene synthesis and DNA cloning aimed to scale back limitations on scientists who want to perform synthetic biology and add their own labs, with their materials, and on their timelines,\u201d said Gibson. \u201cWe also are expanding our vector repertoires and our DNA design capabilities, giving our users workflows that seamlessly build and iterate.\u201d
\n\u201cCodex DNA strives to democratize synthetic biology, and therefore the BioXp\u2122 3250 system launch may be a major step toward achieving that mission,\u201d said Nelson. \u201cWe believe this might be a big role for events like life-saving vaccines and biologics, it’s going to pave the way to increase adoption for the synthetic biological approach in areas to improve human health.\u201d<\/p>\n